Core Viewpoint - New Henghui, a provider of chip packaging materials and testing services, successfully listed on the Growth Enterprise Market, with its stock price surging by 290.62% at opening and currently standing at a 247.11% increase from the issue price [2] Company Overview - New Henghui integrates research, production, sales of chip packaging materials, and packaging testing services, focusing on smart card business, etching lead frame business, and IoT eSIM chip testing services [2] - The smart card business is the company's traditional core, contributing significantly to revenue and profit through the development and sales of flexible lead frame products [2] Business Partnerships - The company has established long-term partnerships with several well-known security chip design manufacturers and domestic and international smart card manufacturers, with applications in communications, finance, transportation, and identity recognition [2] New Business Growth - Significant investments in the etching lead frame and IoT eSIM chip testing sectors have led to the successful development of core technologies, resulting in batch production and sales [3] - Sales revenue from these new businesses for the reporting periods were 110.65 million, 97.83 million, 156.94 million, and 115.00 million yuan, accounting for 20.81%, 14.70%, 21.08%, and 28.71% of main business income respectively [3] Patent Holdings - As of June 30, 2024, the company holds 59 authorized patents, including 32 invention patents [4] Shareholder Structure - The major shareholders are Yu Renrong and Ren Zhijun, holding 31.94% and 19.31% of shares respectively, with Yu also serving as a director [4] Notable Individual - Yu Renrong is also the actual controller of Weir Shares and was ranked first in the Chinese chip industry billionaire list in 2022 with a net worth of 95 billion yuan [5]

Key Takeaways Bayer has filed an NDA with the FDA for gadoquatrane, a low-dose gadolinium MRI contrast agent. Gadoquatrane cuts gadolinium dose by about 60% compared to current macrocyclic GBCAs. QUANTI studies showed gadoquatrane improves image quality with no new safety concerns in adults or children.Bayer (BAYRY) announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use in c ...

Key Takeaways GE HealthCare launched the bkActiv S Series for image-guided, non-surgical urology and pelvic procedures. GEHC's bkActiv S Series offers AI tools, TruSense tech, and single-handed controls for clinician efficiency. GEHC aims to grow recurring revenue through transducer sales, service contracts, and software upgrades.GE HealthCare Technologies Inc. (GEHC) recently expanded its bkPortfolio family of Active Imaging systems with the launch of the bkActiv S Series, a next-generation ultrasound so ...

Core Insights - Klotho Neurosciences, Inc. has terminated its Share Exchange Agreement with SkyBell Technologies, allowing the company to focus on its core R&D programs and enhance shareholder value [2][3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company specializing in innovative, disease-modifying cell and gene therapies derived from the anti-aging human Klotho gene, targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [4] Strategic Implications - The termination of the agreement eliminates the need to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of Klotho, thereby preventing significant dilution of existing shareholders [7] - The company will not incur any liability as a result of this termination, allowing it to refocus its strategy and allocate resources towards advancing its primary therapeutic and longevity programs [7]

We all wear a mask. Some of us just wear so many we forget our real face. Let me show you mine.Who is it. Come in. Hey, Mommy's Princess.Yes, you can get a snack. Close mommy door behind you. Glow is not just another girls organization.We are the organization. So, if we're really going to make the impact that we say we're making, there must be measurements. You let me know when it's done.Yes, bae. No, I do not know where your glasses are. I'll be done in a minute, baby.Just like the different masks you've j ...

Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting t ...

FORT WORTH, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- Brandon Sisson, CEO of Redacted Optics, today issued the following statement to shareholders following the formal transition of VNUE, Inc. (OTC: VNUE) operations and assets: “It’s hard to put into words the work, sacrifice, and belief it has taken to build this company. What started as a focused mission to innovate the optics space has grown into something far greater—something with the potential to reshape how defense, law enforcement, and sportsmen ope ...

Core Insights - Quantum BioPharma Ltd. has initiated a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring myelin integrity in multiple sclerosis (MS) patients [1][2] - The study utilizes the PET tracer [F]3F4AP, which has shown high sensitivity to demyelinated lesions and favorable pharmacokinetics in previous studies, indicating its potential as a biomarker for monitoring demyelination [1][3] - The new combined GE Signa PET-MR scanner at MGH enhances the imaging process by allowing simultaneous acquisition of PET and MRI signals, improving the accuracy of monitoring demyelination over time [2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in MS [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

ProMIS Neurosciences (PMN) FY Conference June 17, 2025 07:00 AM ET Speaker0 Hello everyone and welcome to this latest series of fireside chats here at the Perspectives on Neurology mini conference hosted by H. C. Wainwright. My name is Ram Selvaraju and I'm a Managing Director and Senior Healthcare Equity Research Analyst here within Wainwright's Equity Research Department. I'm joined here today by Neil Warmah, Chief Executive Officer of Promise Neurosciences, a publicly traded biotechnology company focusin ...

SAN FRANCISCO, June 16, 2025 (GLOBE NEWSWIRE) -- The RealReal (Nasdaq: REAL)—the world’s largest online marketplace for authenticated, resale luxury goods—on June 13, 2025, paid the remaining $26,749,000 in aggregate principal amount of its 3% Convertible Senior Notes due 2025 (“2025 Notes”). The RealReal has reduced indebtedness by a total of $63 million year to date and $81 million over the last 16 months. Ajay Gopal, The RealReal’s Chief Financial Officer, stated, “The paydown of our remaining 2025 Notes ...